MAP Pharmaceuticals develops and plans to commercialize new drugs for children and adults who suffer from diseases that we believe are not treated adequately by currently available medicine.
MAP Pharmaceuticals is developing a proprietary nebulized version of budesonide for pediatric asthma
MAP Pharmaceuticals is developing a proprietary inhaled treatment for migraine headache
Proprietary aerosol delivery and pharmacological profiling technology